EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of pTDP ‐43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis

Qi-Jie Zhang, Jie Lin, You-Liang Wang, Long Chen, Ying Ding, Fu-Ze Zheng, Huan-Huan Song, Ao-Wei Lv, Yu-Ying Li, Qi-Fu Guo, Min-Ting Lin, Wei Hu und 10 weitere

Brain Pathology · 2024-11 · 34 (6)

DOI: 10.1111/bpa.13261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Pathology, online erschienen am 11.04.2024. Verfasst von Qi-Jie Zhang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Biomarkers, DNA-Binding Proteins, Muscle, Skeletal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Funds for the Innovation of Science and Technology of Fujian Province, 2021 Provincial Special Subsidy Funds for Health (Biobank Construction Project for Neurological Diseases), National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, pathologically characterized by TDP‐43 aggregates. Recent evidence has been indicated that phosphorylated TDP‐43 (pTDP‐43) is present not only in motor neurons but also in muscle tissues. However, it is unclear whether testing pTDP‐43 aggregation in muscle tissue would assist in the diagnosis of ALS. We propose three key questions: (i) Is aggregation of pTDP‐43 detectable in routine biopsied muscles? (ii) Can detection of pTDP‐43 aggregation discriminate between ALS and non‐ALS patients? (iii) Can pTDP‐43 aggregation be observed in the early stages of ALS? We conducted a diagnostic study comprising 2 groups: an ALS group in which 18 cases underwent muscle biopsy screened from a registered ALS cohort consisting of 802 patients and a non‐ALS control group, in which we randomly selected 54 muscle samples from a biospecimen bank of 684 patients. Among the 18 ALS patients, 3 patients carried pathological GGGGCC repeats in the C9ORF72 gene, 2 patients carried SOD1 mutations, and 7 patients were at an early stage with only one body region clinically affected. The pTDP‐43 accumulation could be detected in routine biopsied muscles, including biceps brachii, deltoid, tibialis anterior, and quadriceps. Abnormal aggregation of pTDP‐43 was present in 94.4% of ALS patients (17/18) compared to 29.6% of non‐ALS controls (16/54; p < 0.001). The pTDP‐43 aggregates were mainly close to the sarcolemma. Using a semi‐quantified pTDP‐43 aggregates score, we applied a cut‐off value of 3 as a diagnostic biomarker, resulting in a sensitivity of 94.4% and a specificity of 83.3%. Moreover, we observed that accumulation of pTDP‐43 occurred in muscle tissues prior to clinical symptoms and electromyographic lesions. Our study provides proof‐of‐concept for the detection of pTDP‐43 accumulation via routine muscle biopsy which may serve as a novel biomarker for diagnosis of ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisBiomarkersDNA-Binding ProteinsMuscle, SkeletalHumansMaleFemaleMiddle AgedAgedBiopsyAdultC9orf72 ProteinCohort StudiesPhosphorylation

Stichwörter der Autor:innen

amyotrophic lateral sclerosisdiagnostic markermuscle biopsypathologyphosphorylated TDP‐43

Substanzen

TARDBP protein, humanBiomarkersDNA-Binding ProteinsC9orf72 ProteinC9orf72 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Neurology, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
  • Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China.
  • Public Technology Service Center, Fujian Medical University, Fuzhou, China.
  • Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Ying Fu

Förderung

  • Joint Funds for the Innovation of Science and Technology of Fujian Province
  • 2021 Provincial Special Subsidy Funds for Health (Biobank Construction Project for Neurological Diseases)
  • National Natural Science Foundation of China
  • Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province

Zitieren

APA

Zhang, Q. J., Lin, J., Wang, Y. L., Chen, L., Ding, Y., Zheng, F. Z., Song, H. H., Lv, A. W., Li, Y. Y., Guo, Q. F., Lin, M. T., Hu, W., Xu, L. Q., Zhao, W. L., Fang, L., Cui, M. C., Fu, Z. F., Chen, W. J., Zhang, J., …, & Fu, Y. (2024). Detection of pTDP ‐43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis. Brain Pathology, 34(6). https://doi.org/10.1111/bpa.13261

Vancouver

Zhang QJ, Lin J, Wang YL, Chen L, Ding Y, Zheng FZ, et al. Detection of pTDP ‐43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis. Brain Pathology. 2024;34(6). doi:10.1111/bpa.13261

BibTeX
@article{Zhang2024,
  author = {Zhang, Qi-Jie and Lin, Jie and Wang, You-Liang and Chen, Long and Ding, Ying and Zheng, Fu-Ze and Song, Huan-Huan and Lv, Ao-Wei and Li, Yu-Ying and Guo, Qi-Fu and Lin, Min-Ting and Hu, Wei and Xu, Liu-Qing and Zhao, Wen-Long and Fang, Ling and Cui, Meng-Chao and Fu, Zhi-Fei and Chen, Wan-Jin and Zhang, Jing and Wang, Zhi-Qiang and Wang, Ning and Fu, Ying},
  title = {Detection of pTDP ‐43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis},
  journal = {Brain Pathology},
  year = {2024},
  volume = {34},
  number = {6},
  doi = {10.1111/bpa.13261}
}
Kostenlos starten →